Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33,955 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM. Gambacorti-Passerini C, et al. Among authors: shi y. Am J Hematol. 2018 May;93(5):607-614. doi: 10.1002/ajh.25043. Epub 2018 Feb 8. Am J Hematol. 2018. PMID: 29352732 Free PMC article. Clinical Trial.
Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients.
Huang LL, Hu XS, Wang Y, Li JL, Wang HY, Liu P, Xu JP, He XH, Hao XZ, Jiang PD, Liu YT, Luo J, Zhou SY, Wang JW, Yang JL, Qin Y, Yuan P, Lin L, Shi YK. Huang LL, et al. Among authors: shi yk. Thorac Cancer. 2021 Jul;12(13):1943-1951. doi: 10.1111/1759-7714.13977. Epub 2021 May 9. Thorac Cancer. 2021. PMID: 33969619 Free PMC article.
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Shi Y, Lei K, Jia Y, Ni B, He Z, Bi M, Wang X, Shi J, Zhou M, Sun Q, Wang G, Chen D, Shu Y, Liu L, Guo Z, Liu Y, Yang J, Wang K, Xiao K, Wu L, Yi T, Sun D, Kang M, Ma T, Mao Y, Shi J, Tang T, Wang Y, Xing P, Lv D, Liao W, Luo Z, Wang B, Wu X, Zhu X, Han S, Guo Q, Liu R, Lu Z, Zhang J, Fang J, Hu C, Ji Y, Liu G, Lu H, Wu D, Zhang J, Zhu S, Liu Z, Qiu W, Ye F, Yu Y, Zhao Y, Zheng Q, Chen J, Pan Z, Zhang Y, Lian W, Jiang B, Qiu B, Zhang G, Zhang H, Chen Y, Chen Y, Duan H, Li M, Liu S, Ma L, Pan H, Yuan X, Yuan X, Zheng Y, Gao E, Zhao L, Wang S, Wu C. Shi Y, et al. Among authors: shi j. Cancer Commun (Lond). 2021 Sep;41(9):889-903. doi: 10.1002/cac2.12179. Epub 2021 Jun 29. Cancer Commun (Lond). 2021. PMID: 34184418 Free PMC article. Clinical Trial.
Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.
Shi J, Chen G, Wang H, Wang X, Han B, Li K, Wang Q, Zhang L, Wang Z, Cheng Y, He J, Shi Y, Chen W, Luo Y, Wu L, Wang X, Nan K, Jin F, Dong J, Li B, Liu Z. Shi J, et al. Among authors: shi y. Thorac Cancer. 2021 Sep;12(17):2345-2351. doi: 10.1111/1759-7714.14076. Epub 2021 Jul 17. Thorac Cancer. 2021. PMID: 34273139 Free PMC article. Clinical Trial.
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
Tan Q, Dai L, Wang Y, Liu S, Liang T, Luo R, Wang S, Lou N, Chen H, Zhou Y, Zhong Q, Yang J, Xing P, Hu X, Liu Y, Zhou S, Yao J, Wu D, Zhang Z, Tang L, Yu X, Han X, Shi Y. Tan Q, et al. Among authors: shi y. Cancer Immunol Immunother. 2022 Jul;71(7):1681-1691. doi: 10.1007/s00262-021-03106-z. Epub 2021 Nov 24. Cancer Immunol Immunother. 2022. PMID: 34817638 Free PMC article.
33,955 results
You have reached the last available page of results. Please see the User Guide for more information.